AstraZeneca Group Market Cap: 63.44B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AZN Market Cap Rankings
| Overall | 98th percentile | 83 of 4673 |
| Sector | 98th percentile | 9 of 530 in Healthcare |
| Industry | 70th percentile | 8 of 27 in Drug Manufacturers - Major |
AZN Market Cap Range, Past 5 Years
| Minimum | 52.74B | Sep 2002 |
| Maximum | 96.94B | Sep 2006 |
| Average | 76.42B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these AZN related companies
AZN News
AstraZeneca (AZN) Broadens AZ&Me Prescription Savings Programs Eligibility
Feb 08, 9:01AM Street Insider
Feb 08, 9:01AM Street Insider
AstraZeneca US Broadens Income Eligibility for Prescription Savings Programs
Feb 08, 9:00AM Business Wire
Feb 08, 9:00AM Business Wire
RT @bradloncar Not impressed w big share buyback $AZN is planning for 2012. Won't help investrs much if they dont figure out innovation soon
about 10 days ago by wallstreetbean
about 10 days ago by wallstreetbean
R&D in Quebec pharma industry continues to erode $AZN $JNJ $SNY $MRK
about 10 days ago by michaelbabad
about 10 days ago by michaelbabad
AstraZeneca (AZN) Announces Restructuring, Will Eliminate 7,300 Positions
Feb 02, 7:18AM Street Insider
Feb 02, 7:18AM Street Insider
RT @wallstreetbean $IPXL "Impax acquires US rights to migraine drug Zomig" http://stks.co/2CIn will pay $AZN $130M and royalties.
about 11 days ago by STheadlines
about 11 days ago by STheadlines
Notable #EarningsReports AfterHours: $CMG $LVS $QCOM $GMCR $TSCO $JDSU PreMarket: $ADS $MA $RGLD $ODFL $AZN $BZH #LeadingStocks #StockMarket
about 11 days ago by CapitalistBull
about 11 days ago by CapitalistBull
Impax (IPXL) Unit Licenses Zomig Rights in U.S. from AstraZeneca (AZN); Updates FY12 Outlook
Feb 01, 8:07AM Street Insider
Feb 01, 8:07AM Street Insider
Impax Labs $IPXL licenses exclusive US commercialization to Zomig from AstraZeneca $AZN, to pay $130M
about 11 days ago by Street_Insider
about 11 days ago by Street_Insider
Impax Labs (IPXL) licenses exclusive US commercialization to Zomig from AstraZeneca (AZN)
Feb 01, 8:01AM Street Insider
Feb 01, 8:01AM Street Insider
@insidermonkey Afternoon Aggregate News: Hedge Funds Took In $3.6 Billion In November, Lampert Cuts $AZN $SHLD http://stks.co/1m1H $AIG $C
about 39 days ago by valuewalk
about 39 days ago by valuewalk
$E, $BMA, $PBR, $AZN 10 picks from a master contrarian http://stks.co/1c0x
about 55 days ago by eyeonequities
about 55 days ago by eyeonequities
$AZN says it's cutting its U.S. sales force by about 24% as part of the company's recent efforts to cut costs.
about 67 days ago by NCFinanceGuy
about 67 days ago by NCFinanceGuy
7 Stocks Hussman Strategic Growth Fund http://stks.co/1PcG $AZN $BIIB $ENDP $HUM $KO $LIFE $PNRA
about 68 days ago by myplaniq
about 68 days ago by myplaniq
$AZO RT @Briefingcom AutoZone Beats First Quarter Expectations http://stks.co/1PEt $AZN
about 68 days ago by wallstreetbean
about 68 days ago by wallstreetbean
@yukikobayashi $TRGT will be back to $10 for sure in a month. Look at the option volume December 17th. $TRGT has cash, $AZN is their back!
about 92 days ago by yukikobayashi
about 92 days ago by yukikobayashi
$AZN 50 Day SMA Cross - Price crossed below 50 day SMA (46.0094). Confirmed by volume.
about 95 days ago by TradeIdeasQuant
about 95 days ago by TradeIdeasQuant
$AZN depression a tricky thing to treat. Was worthwhile, but risky bet. Still other studies to complete with TC-5214 though...may be viable.
about 96 days ago by wallstreetbean
about 96 days ago by wallstreetbean
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 47.16 | -0.33 | -0.69% | 63.44B |
| FVE | 3.50 | -0.15 | -4.11% | 166.46M |
| GCI | 14.61 | -0.42 | -2.79% | 3.48B |
| RKT | 68.04 | 0.53 | 0.79% | 4.80B |
| UNP | 111.63 | -1.17 | -1.04% | 53.93B |
| IMN | 6.09 | -0.07 | -1.14% | 232.15M |
| NDN | 22.01 | 0.02 | 0.09% | 1.55B |
| FMC | 91.18 | -1.62 | -1.75% | 6.42B |
| ACAS | 8.69 | 0.15 | 1.76% | 3.00B |
| INTC | 26.70 | -0.17 | -0.61% | 135.93B |
